

Update On Diabetes

1 hour

Steven Ferrucci, OD, FAAO

Description:

This course will discuss some of the newest development in diabetes and diabetic eye care, focusing on new advances in treatment and management of diabetic retinopathy as well as systemic issues

Learning Objectives:

- Review the current treatment options for diabetes, diabetic retinopathy, and diabetic macular edema
- Discuss treatment options that are currently under development for diabetes, diabetic retinopathy, and diabetic macular edema.
- Understand the latest treatment options for our patients with diabetes, diabetic retinopathy, and diabetic macular edema.

Outline:

1. Introduction
2. Systemic issues
 - a. Types of DM
 - i. Type 1
 - ii. Type 2
 - iii. Gestational DM
 - iv. LADA Type 1.5
 - b. Diagnosis
 - i. Traditional
 1. FBS.126 mg/dl
 2. OGTT>200
 - ii. A1c >6.5

1. Advantages: no fasting, more convenient, more accurate
 2. Disadvantages: perhaps increased cost
 - c. Current recommendations for care of Pt with DM
 - i. Control BS
 - ii. Control BP
 - iii. Control Chol
 - iv. No smoking, exercise
 - v. Yearly DFE
3. Diabetic retinopathy
- a. Prevalence/incidence
 - b. Risk factors
 - i. Duration of disease
 - ii. Control of BS
 1. A1c/
 2. Time in range (TIR)
 - c. Staging
 - i. NPDR
 1. Mild
 - a. Characteristics
 - b. Follow- up
 2. Moderate
 - a. Characteristics
 - b. Follow- up
 3. Severe/very severe
 - a. Characteristics
 - b. Follow- up
 4. When to refer
 - a. Anti-VEGF Studies

- i. RISE/RIDE
 - ii. Panorama/Eylea
 - iii. Fate f 47
 - ii. PDR (Including high-risk)
 - 1. Characteristics
 - 2. Follow- up
 - 3. When to refer
 - 4. Treatments
 - a. PRP vs anti-VEGF
 - b. Pros/cons
 - i. Protocol S
 - iii. DME
 - 1. Incidence
 - 2. Characteristics
 - 3. Center-involved vs. non-CI
 - 4. Follow- up
 - 5. Treatments
 - a. Anti-VEGF
 - b. Steroids
 - c. Observation
 - i. Protocol V
- 4. Treatment options
 - a. Anti-Vegf
 - i. How they work
 - ii. Pros/cons
 - iii. The OG
 - 1. Macugen
 - 2. Lucentis
 - 3. Eylea

4. Beovu

5. Avastin

iv. Newer agents

1. Faricimab

2. High-dose (HD) Eylea

3. Biosimilars

4. Susvimo

5. In development

5. Imaging

a. Widefield

i. Importance

ii. Hand held options

b. ERG

i. DR protocol

1. How to use

2. Cases

6. Conclusions/take home